TNFRSF8 and neoplasm: Studies have shown that the MMAE portion of BV can be released into TME with the breakdown of CD30+lymphoma cells, and MMAE can freely cross the cell membrane, so it can play a bystander effect in TME for anti-tumor effects, which also explains why BV treatment is still effective when the expression rate of CD30 in lymphoma is low (59, 60) (Figure 3).